The weight loss drug set to shape up the medtech world

Glucagon‑like peptide‑1 receptor agonists (GLP‑1s) have been around for a while – decades in fact. But since proving effective as a weight loss drug, they've been a very hot topic. The World Health Organization'S latest data shows that there were 890 million adults living with obesity worldwide in 2022. Naturally, a drug that can combat this global pandemic has significant potential. But its success could mean demand for surgery and treatments for obesity could decline significantly. So what do investors need to know about GLP-1s? This article from T. Rowe Price explores the history...